The European Commission announced on Wednesday that it had entered into a contract with the US pharmaceutical company Novavax for the advance purchase of 200 million doses of its vaccine once it has been approved by the European Medicines Agency.
Read also: Novavax says its anti-Covid vaccine is more than 90% effective, including against variants
"
Our new agreement with Novavax expands our vaccine portfolio by adding another protein-based vaccine, a platform that shows promise in clinical trials,
" Health Commissioner Stella Kyriakides said in a statement.